

الملخص العربي

ان مرض السدة الرئوية المزمنة هو مرض مزمن ينتج عن انسداد الشعب الهوائيه نتيجة التدخين المستمر ,والتدخين هو عامل مشترك بين مرضي السده الرئويه المزمنه ومرضي الشرايين التاجيه وهو ايضا اساسي في تشخيص مرض السده الرئويه لذلك ان عمليات تغيير الشرايين التاجيه من العمليات الاساسيه في مرضي قصور الشرايين التاجيه .

ان عمليات تغيير الشرايين التاجيه لها العديد من التحضيرات التي تسبق العمليه وهي من العمليات التي تحتاج الي متابعه بعد العمليه نظرا لخطورتها علي المرضى.

يوجد ارتباط وثيق بين مرضي السده الرئويه المزمنه وبين مرضي قصور الشرايين التاجيه, توجد اربعة اسباب لهذه العلاقه منها تشابه الجينات الوارثيه بين الاثنين,والالتهابات الشديده التي يسببها مرض السده الرئويه المزمنه,تمدد الحويصلات الهوائيه في الرئتين وارتفاع ضغط الشريان الرئوي.

هذه الرساله تمت لمعرفه تاثير عمليات جراحه تغيير الشرايين التاجيه علي مرضي السده الرئويه المزمنه ودراسه المضاعفات الناتجه عن العمليه.

تبينت من احصائيات هذه الرساله انه يوجد قصور كبير في وظائف التنفس لهؤلاء المرضى منها انخفاض كبير في مخزون الهواء من الرئه وانخفاض في كميّه الهواء داخل الحويصلات الهوائيه الصغيره ووجود ارتفاع ملحوظ في وظائف الكبد ووجود بعض التغييرات في غازات الدم بعد العمليه.

تاثير هذه العمليه علي مرضي السده الرئويه المزمنه كان نتيجة الالتصاقات في عظمه القص, وقصور في عمل عضله الحجاب الحاجز, وتغيير كبير في تبادل الغازات في الشعب الهوائيه , ووجود المريض علي ماكينه القلب الصناعي يعمل علي تراكم البصاق بشكل كبير والتصاق الشعبيات الهوائيه الصغيره وعدم وصول الدم بشكل منتظم الي العضلات.

تم تسجيل العديد من المضاعفات لمرضي السده الرئويه المزمنه منها الانسكاب البلوري الذي يشمل

40% من الحالات,الالتهابات الرئوية في 8% من الحالات,تضخم متزايد في عضله القلب, وتزايد حده مرض السده الرئويه المزمنه وهذه المضاعفات قد تجعل المريض بحاجة للمكوث في الرعاية المركزه لفترات اطول وقد تصل الي التهاب رئوي نتيجة جهاز التنفس الصناعي والذي قد يتسبب في وفاه المريض بنسبه قد تصل الي 75 % من هذه الحالات وقد يحدث ارتشاح رئوي في بعض الحالات نتيجة ضعف في عضله القلب والتي تتطلب وجود المريض علي جهاز التنفس الصناعي لفترات اطول.

يوصي بعمل اعاده تاهيل لهؤلاء المرضى عن طريق الحركه المبكرة للمرضي والذي يساعد عي تحسن وعي المريض وحالته الذهنية وعدم تعرضه لجلطات القدم ,وتنشيط كهربائي للعضلات وكذلك استخدام بعض الاجهزه التي تساعد علي زياده قدره الرئه علي استيعاب الهواء وتحسن وظائف التنفس.

تبين من الرساله انه يوجد قصور في وظائف التنفس لمرضي السده الرئوية المزمنة وضعف في القدره الاستعابية للرئتين ووجود مضاعفات عديده لهذا النوع من العمليات ,وان عمليات تغيير الشرايين التاجيه لها تاثير طويل علي مرضي السده الرئوية المزمنة لذلك ينصح بعمل وظائف تنفس لهؤلاء المرضى قبل وبعد العمليه وعمل تاهيل طبيعي لهؤلاء المرضى.

ACKNOWLEDGEMENT

Beyond all thanks, many thanks to Allah most gracious, most merciful, for helping me throughout the progress of this work which carries the imprint of many who made a significant contribution to its development, and for blessing me with my family that supported me in every step throughout my life.

I would like to express my deepest gratitude and indebtedness to Prof. **Dr.Laila Ashour Helalah** Professor of Chest, Faculty of Medicine, University of Ain Shams, who devoted much of his time and showed a great interest in providing me with valuable criticism and informing guidance and encouragement, and supported me all through the study.

The great thanks to my leaving father, mother and to my wife.

Many thanks and appreciation to Dr. **Ibrahim ali Dwedar** Assistant Professor of Chest, Faculty of Medicine, University of Ain Shams, for the time he gave to me, his support, his patience and willingness to provide continuous guidance have been instrumental in bringing the study to completion.

Last, but not least, I want to express my cordial feelings towards my dear professors in our department, to whom I owe a lot of things more than I can count.

LIST OF CONTENTS

Chapter	Page
ACKNOWLEDGEMENT	I
LIST OF CONTENTS	Ii
LIST OF TABLES	Iii
LIST OF FIGURES	iv
LIST OF ABBREVIATION	v
INTRODUCTION	
Chronic Obstructive Pulmonary Disease	1
Coronary Artery Bypass Grafting	18
Combined risk factors in Ischemic heart disease and chronic obstructive pulmonary disease	28
Different coronary artery bypasses grafting methods in chronic obstructive pulmonary disease patient	37
AIM OF THE WORK	42
SUBJECTS AND METHODS	43
RESULTS	47
DISCUSSION	63
CONCLUSION	82
SUMMARY	83
REFERENCES	86
ARABIC SUMMARY	105

LIST OF TABLES

Table		Page
Table (1)	The analysis of the age values.	47
Table (2)	The analysis of preoperative distribution of radiographic signs	48
Table (3)	The analysis of postoperative distribution of radiographic signs.	49
Table (4)	The analysis of perioperative radiographic changes.	50
Table (5)	The analysis of perioperative changes of (SGOT)	51
Table (6)	The analysis of perioperative changes of (SGPT).	52
Table (7)	The analysis of perioperative changes of creatinine	53
Table (8)	The analysis of perioperative changes of PH of Arterial Blood Gases.	54
Table (9)	The analysis of perioperative changes of Arterial oxygen tension(PO ₂)of Arterial Blood Gases.	55
Table (10)	perioperative changes of carbon dioxide tension(PCO ₂) of Arterial Blood Gases.	56
Table (11)	Perioperative changes of HCO ₃ of Arterial Blood Gases.	57
Table (12)	perioperative changes of Forced Expiratory volume in the 1 ST second(FEV ₁)of Pulmonary Function Test.	58
Table (13)	Perioperative changes of Peak Expiratory Flow Rate (PEF) of pulmonary function test.	59
Table (14)	Perioperative changes of Forced Vital Capacity (FVC) of Pulmonary Function Test(PFT).	60
Table (15)	perioperative changes of the ratio between Forced Expiratory volume in the 1 ST second(FEV ₁)and Forced vital capacity (FVC)of Pulmonary Function Test.	61
Table (16)	Perioperative changes of Peak Expiratory Flow Rate (PEF) of Pulmonary Function Test(PFT).	62
Table (17)	The analysis of postoperative complications,	63

LIST OF FIGURES

Figure		Page
Figure (1)	Pathophysiology of COPD.	3
Figure (2)	Chest X ray shows hyperinflated lung.	9
Figure (3)	Noninvasive mechanical ventilation.	17
Figure (4)	The principle of CABG operation.	23
Figure (5)	A pie chart showing preoperative distribution of radiographic signs.	47
Figure (6)	Postoperative distribution of radiographic signs.	48
Figure (7)	A chart showing perioperative changes of (SGOT).	50
Figure (8)	A chart showing perioperative changes of (SGPT).	51
Figure (9)	Perioperative changes of creatinine.	52
Figure (10)	Perioperative changes of PH of Arterial Blood Gases.	53
Figure (11)	Perioperative changes of arterial oxygen tension.	54
Figure (12)	Perioperative changes of arterial carbon dioxide tension.	55
Figure (13)	Perioperative changes of Hco ₃ .	56
Figure (14)	Perioperative changes of Forced Expiratory volume in the 1ST second(FEV1).	57
Figure (15)	Perioperative changes of Peek Expiratory Flow Rate.	58
Figure (16)	Perioperative changes of Forced Expiratory volume.	59
Figure (17)	Perioperative changes of FEV1/FVC.	60
Figure (18)	Perioperative changes of PEF 25-75.	61
Figure (19)	Postoperative pulmonary complication.	62
Figure (20)	Chest X ray shows postoperative atelectasis.	70
Figure (21)	Chest X ray shows postoperative pleural effusion.	72

ASCVD	Atherosclerotic cardiovascular vascular disease.
ACB	Aorta coronary bypass.
ARDS	Acute respiratory distress syndrome.
BLVR	Broncoscopic lung volume reduction.
BMI	Body mass index.
CABG	Coronary artery bypasses grafting.
CPB	Cardiopulmonary bypass.
COPD	Chronic obstructive pulmonary disease.
CAD	Coronary artery disease.
DD	Differential diagnosis.
DVT	Deep venous thrombosis.
ECG	Electrocardiogram.
FVC	Forced vital capacity.
FEV1	Forced expiratory volume in the 1 st second
ICU	Intensive care unit.
IS	Incentive spirometry.
IMA	Internal mammary artery.
KFT	Kidney function test.
LAD	Left anterior descending.
LFT	Liver function test.
LIMA	LeftInternal mammary artery.
MV	Mechanical ventilation.
NIPPV	Noninvasive positive pressure ventilation.
NEMS	Neuro muscular electrical stimulation
PO2	Arterial oxygen tension.
PCO2	Arterial carbon dioxide tension.
PTCA	Percutaneous trans luminal coronary angiography.
PFT	Pulmonary function test.
PTI	The percentage thickness increase.
RCA	Right coronary artery.
SFL	Smoking free legislation.
SaO2	Arterial oxygen saturation.

Chronic Obstructive Pulmonary Disease

Definition:

COPD is a mostly preventable and treatable disorder characterized by expiratory airflow limitation that is not fully reversible.

The air flow limitation is often progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases especially cigarette smoking. ^(1, 2)

Epidemiology:

COPD is a major cause of morbidity and mortality worldwide. ⁽³⁾ Although the prevalence of COPD is difficult to determine is estimated to affect about 24 million American. ⁽⁴⁾

COPD and other chronic lower respiratory tract represent the third leading cause of death in the United States. Chronic obstructive pulmonary disease is projected to rank as the fifth worldwide burden of disease by 2020. ⁽⁵⁾

Epidemiology in Egypt:

In Egypt there is about 3.77 million COPD patient according to the last survey done in Egypt in 2010⁽⁶⁾.

Etiology of COPD:

COPD occurs in 10-20 % of smokers indicating that there is probable genetic susceptibility.

Exposures to:

1- Tobacco smoke: Cigarette smoking is by far the most important risk factor for COPD either active or passive exposure to smoke as well as fetal affection in pregnant females.⁽⁷⁾

2- Occupational dusts and chemicals: When the exposures are sufficiently intense or prolonged, such as those experienced by miners in many countries.⁽⁸⁾

3- Outdoor and indoor air pollution: Although the issue is not settled, available evidence suggests that air pollution might be a factor in the development of COPD.⁽⁹⁾

Genes:

Alpha 1-antitrypsin deficiency is found in 1-2 of COPD patients clinical characteristics of affected patients may include a minimal smoking history, early onset COPD younger than 45 years old also a family history of lung disease or lower lobe predominant.⁽¹⁰⁾

Pathophysiology of COPD

Processes in the lungs and airways are important in the pathogenesis of COPD include:

- Mucous gland hyperplasia particularly in the large airways, with mucous gland hypersecretion and therefore a chronic productive cough is produced.⁽¹¹⁾
- Mucosal damage from smoke, squamous metaplasia and replacement of the normal ciliated columnar epithelium by squamous epithelium as shown in figure (1)
- Chronic inflammation and fibrosis of small air way characterized by CD8 lymphocyte, Macrophage and Neutrophils infiltration with release of pro-inflammatory cytokines.⁽¹²⁾
- Emphysema due to alveolar wall destruction causing irreversible enlargement of air spaces distal to the terminal bronchioles with subsequent loss elastic recoil and hyperinflated lungs.⁽¹³⁾
- The thickened pulmonary arteriolar wall and remodeling occurs with hypoxia leads to increased pulmonary vascular resistance, pulmonary hypertension and impaired gas exchange. (Barbera et al., 2003).




Figure (1): shows Pathophysiology of COPD

Clinical aspect of COPD:

- **COPD** is a heterogeneous disease: two main phenotypes of the disease are recognized **chronic bronchitis and emphysema**.
- **Chronic bronchitis** is characterized by cough and sputum production for 3 months in each of two consecutive years.⁽¹⁵⁾
- **Emphysema** is defined as destruction of the airways distal to the terminal bronchioles and gradual destruction of the alveolar septa and the pulmonary capillary bed.⁽¹⁴⁾
- The symptoms may precede the development of air flow limitation by many years. Inflammation and secretion provide the obstructive component of the disease, in contrast to emphysema chronic bronchitis is associated with relatively undamaged pulmonary capillary. The body responds by decreasing ventilation and increasing cardiac output (ventilation -perfusion mismatch) leading to hypoxia, polycythemia and increased carbon dioxide retention and eventually these patients develop signs of right sided heart failure.⁽¹⁶⁾

COPD Severity according to NICE Guidelines:

- **Mild:** FEV1 50-80% predicted may or may not be symptomatic.

- **Moderate:** FEV1 30-49 % Predicted, Increased FRC, Reduced DLCo likely to be symptomatic (cough, sputum, dyspnea).
- **Severe:** FEV1 <30% predicted with marked hyperinflation, TLCO usually low with signs of cor pulmonale.

Classification based on post bronchodilator FEV1: GOLD2014

- **Mild** FEV1 >80 % predicted.
- **Moderate** 50% < FEV1 < 80%.
- **Severe** 30% < FEV1 < 50%.
- **Very severe** FEV1 < 30% .

Clinical features:

History:

Patient exposed to risk factor such as smoking and occupational or environmental exposure. ⁽³⁸⁾

Symptoms:

- **Cough:** chronic cough, usually the first symptom of COPD to develop,

intermittent at the beginning then becoming progressive throughout the day.⁽¹⁸⁾

- **Sputum:** initially occurs in the morning but later will be present all day long. It is usually tenacious and mucoid and in small quantities. A change in sputum color (purulent) or volume suggests an infective exacerbation.⁽¹⁹⁾
- **Hemoptysis:** it is not uncommon during exacerbation; however the presence of blood should always alert the physician to the possibility of alternative diagnosis.⁽²⁰⁾
- **Dyspnea:** is usually progressive and over time it becomes persistent. It is the reason most patients seek medical attention and is a major cause of disability and anxiety associated with the disease.⁽²¹⁾
- **Wheezing and chest tightness:** are relatively non-specific, in stage II, stage III and stage IV particularly during exercise.
- Weight loss may occur with end stage COPD.

Signs:

Depend on the severity of the underlying disease:

- Raised respiratory rate.
- Barrel shaped chest.
- Resonant bare area of the heart.
- Use of accessory muscle of respiration.

- Quite breath sound.
- Signs of cor-pulmonale and co2 retention (ankle oedema, raised juglar venous pressure, plethoric conjunctiva and polycythemia).⁽²²⁻²³⁾

Extra pulmonary aspects of COPD

Cardiovascular diseases

- Ischaemic heart disease.
- Hypertension.
- Pulmonary hypertension.
- Congesive heart failure.

Metabolic disorder

- Osteoporosis.
- Skeletal muscle weakness.
- Cachexia: weight loss and muscle wasting.
- Diabetes mellitus.
- Metabolic syndrome.

Other co morbid diseases:

- Lung cancer.
- Chronic kidney disease.